Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. It is grouped under the following drug class(es): Biologics. Its therapeutic use is listed as hematologic agents. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include Neulasta. Its PubChem CID is 70683024.
Pegfilgrastim
| CAS No | 208265-92-3 |
|---|---|
| Molecular Formula | C27H46N4O19 |
| Molecular Weight | 730.7 g/mol |
| Synonyms | (2R,4S,5R,6R)-2-[[(2R,3R,4R,5R,6S)-5-acetamido-6-[(1S,2R)-1-amino-1-carboxypropan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]methoxy]-4-hydroxy-5-[[2-(2-methoxyethoxycarbonylamino)acetyl]amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim].
The listed CAS number is 208265-92-3.
The listed molecular formula is C27H46N4O19.
The listed molecular weight is 730.7 g/mol.
(2R,4S,5R,6R)-2-[[(2R,3R,4R,5R,6S)-5-acetamido-6-[(1S,2R)-1-amino-1-carboxypropan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]methoxy]-4-hydroxy-5-[[2-(2-methoxyethoxycarbonylamino)acetyl]amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.
The source lists Neulasta.